Additional confirmations of the critical survival support of CLL cells by TAMs come also from the study of Galletti et al. These authors, by the use of a CLL/xenograft model, have demonstrated that targeting of mono/macrophages by either CSFR1 (colony-stimulating factor-1 receptor) or liposomal clodronate markedly inhibited leukemia development further restoring an anti-leukemic phenotype in accessory cells of the microenvironment [71,72]. This evidence concerns the gene CSF1R and B-cell chronic lymphocytic leukemia.